Total Payments
$152,308
2024 Payments
$80,145
Companies
14
Transactions
100
Medicare Patients
272
Medicare Billing
$26,781
Payment Breakdown by Category
Research$136,452 (89.6%)
Consulting$9,430 (6.2%)
Travel$4,392 (2.9%)
Food & Beverage$2,034 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $136,452 | 49 | 89.6% |
| Consulting Fee | $9,430 | 4 | 6.2% |
| Travel and Lodging | $4,392 | 18 | 2.9% |
| Food and Beverage | $2,034 | 29 | 1.3% |
Payments by Type
Research
$136,452
49 transactions
General
$15,856
51 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $130,382 | 28 | $0 (2024) |
| SANOFI US SERVICES INC. | $5,853 | 19 | $0 (2023) |
| Janssen Global Services, LLC | $3,805 | 3 | $0 (2021) |
| PFIZER INC. | $3,220 | 2 | $0 (2022) |
| Boehringer Ingelheim b.v. | $3,193 | 5 | $0 (2017) |
| AstraZeneca UK Limited | $1,787 | 9 | $0 (2017) |
| Lexicon Pharmaceuticals, Inc. | $1,626 | 3 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $1,244 | 12 | $0 (2023) |
| AbbVie, Inc. | $922.78 | 9 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $136.79 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $80,145 | 6 | Eli Lilly and Company ($78,497) |
| 2023 | $3,674 | 24 | SANOFI US SERVICES INC. ($1,701) |
| 2022 | $3,229 | 3 | PFIZER INC. ($3,200) |
| 2021 | $979.50 | 2 | Janssen Global Services, LLC ($870.00) |
| 2020 | $3,710 | 3 | Janssen Global Services, LLC ($2,935) |
| 2019 | $21,643 | 25 | Eli Lilly and Company ($18,555) |
| 2018 | $33,821 | 19 | Eli Lilly and Company ($31,715) |
| 2017 | $5,106 | 18 | Boehringer Ingelheim b.v. ($3,193) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $70,113.00 | Research |
| Study: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $8,384.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 03/19/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $1,158.89 | Research |
| Study: LX9211 | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $248.02 | Research |
| Study: LX9211 | ||||||
| 02/16/2024 | Lexicon Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $219.25 | Research |
| Study: LX9211 | ||||||
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $258.23 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $258.23 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $145.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $145.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Travel and Lodging | In-kind items and services | $117.11 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 10/11/2023 | Boehringer Ingelheim International GmbH | — | Food and Beverage | In-kind items and services | $40.00 | General |
| 10/06/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | Cash or cash equivalent | $22.05 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $447.93 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $336.74 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $283.89 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $69.99 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $53.26 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
| 09/22/2023 | SANOFI US SERVICES INC. | DUPIXENT (Biological) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma • Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $70,113 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $30,915 | 4 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $10,631 | 3 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $9,114 | 2 |
| DANUGLIPRON CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| safety and efficacy linagliptin vs SU | Boehringer Ingelheim b.v. | $3,193 | 5 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Dia | SANOFI US SERVICES INC. | $2,076 | 4 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia | SANOFI US SERVICES INC. | $2,076 | 4 |
| A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | SANOFI US SERVICES INC. | $1,701 | 11 |
| LX9211 | Lexicon Pharmaceuticals, Inc. | $1,626 | 3 |
| M16-100 | AbbVie, Inc. | $922.78 | 9 |
| A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | Eli Lilly and Company | $884.23 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 84 | 99 | $26,013 | $8,720 |
| 2022 | 5 | 84 | 98 | $23,688 | $8,399 |
| 2021 | 5 | 67 | 78 | $17,539 | $6,557 |
| 2020 | 2 | 37 | 46 | $12,220 | $3,105 |
Total Patients
272
Total Services
321
Medicare Billing
$26,781
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 42 | $12,768 | $3,994 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 33 | $6,798 | $2,125 | 31.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 13 | 13 | $4,654 | $1,882 | 40.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 11 | 11 | $1,793 | $719.30 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 34 | $10,336 | $3,427 | 33.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 15 | 15 | $5,370 | $2,246 | 41.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 25 | $5,150 | $1,493 | 29.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 12 | 12 | $1,956 | $815.92 | 41.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 12 | 12 | $876.00 | $417.22 | 47.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 25 | $7,600 | $2,613 | 34.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 11 | 11 | $3,531 | $1,708 | 48.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 18 | $3,708 | $1,211 | 32.7% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 12 | 12 | $1,824 | $783.12 | 42.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 12 | 12 | $876.00 | $240.84 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 28 | $8,512 | $2,303 | 27.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 17 | 18 | $3,708 | $801.55 | 21.6% |
About Dr. Nabil Andrawis, M.D
Dr. Nabil Andrawis, M.D is a Internal Medicine healthcare provider based in Burke, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356310551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nabil Andrawis, M.D has received a total of $152,308 in payments from pharmaceutical and medical device companies, with $80,145 received in 2024. These payments were reported across 100 transactions from 14 companies. The most common payment nature is "" ($136,452).
As a Medicare-enrolled provider, Andrawis has provided services to 272 Medicare beneficiaries, totaling 321 services with total Medicare billing of $26,781. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Burke, VA
- Active Since 03/17/2006
- Last Updated 07/12/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1356310551
Products in Payments
- TRULICITY (Drug) $31,993
- TRADJENTA (Drug) $3,193
- EFPEGLENATIDE (Drug) $2,076
- SAR439977 (Drug) $2,076
- DUPIXENT (Biological) $1,701
- Androgel (Drug) $922.78
- JARDIANCE (Drug) $74.11
- ENTRESTO (Drug) $29.20
- Rybelsus (Drug) $22.23
- PREVNAR - 13 (Biological) $20.40
- JANUVIA (Drug) $13.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Burke
Dr. Nashwa Gabra, M.d, M.D
Internal Medicine — Payments: $149,145
Internal Medicine $149,145
Puneet Narayan, Md, MD
Internal Medicine — Payments: $1,155
Internal Medicine $1,155
Dr. Robert Posner, M.d, M.D
Internal Medicine — Payments: $210.93
Internal Medicine $210.93
Dr. Vasudha Narayana, Md, MD
Internal Medicine — Payments: $45.23
Internal Medicine $45.23
Dr. Katherine Rutledge, Md, MD
Internal Medicine — Payments: $17.94
Internal Medicine $17.94
Krysta Frye, Md, MD
Internal Medicine — Payments: $14.44
Internal Medicine $14.44